Alnylam Pharmaceuticals/$ALNY
13:30
03:10
16:45
06:25
20:00
1D1W1MYTD1Y5YMAX
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Ticker
$ALNY
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
2,230
ISIN
US02043Q1076
Website
ALNY Metrics
BasicAdvanced
$41B
-
-$2.10
0.30
-
Price and volume
Market cap
$41B
Beta
0.3
52-week high
$317.54
52-week low
$153.23
Average daily volume
911K
Financial strength
Current ratio
3.038
Quick ratio
2.836
Long term debt to equity
2,247.54
Total debt to equity
2,358.255
Interest coverage (TTM)
-0.79%
Profitability
EBITDA (TTM)
-57.815
Gross margin (TTM)
86.01%
Net profit margin (TTM)
-11.49%
Operating margin (TTM)
-4.91%
Effective tax rate (TTM)
24.11%
Revenue per employee (TTM)
$1,050,000
Management effectiveness
Return on assets (TTM)
-1.79%
Return on equity (TTM)
519.47%
Valuation
Price to revenue (TTM)
17.096
Price to book
352.57
Price to tangible book (TTM)
352.57
Price to free cash flow (TTM)
-532.523
Free cash flow yield (TTM)
-0.19%
Free cash flow per share (TTM)
-58.65%
Growth
Revenue change (TTM)
17.21%
Earnings per share change (TTM)
-20.76%
3-year revenue growth (CAGR)
38.70%
10-year revenue growth (CAGR)
44.10%
3-year earnings per share growth (CAGR)
-34.57%
10-year earnings per share growth (CAGR)
0.19%
What the Analysts think about ALNY
Analyst ratings (Buy, Hold, Sell) for Alnylam Pharmaceuticals stock.
Bulls say / Bears say
Alnylam's Amvuttra received FDA approval for treating ATTR-CM, expanding its market reach and positioning it as a competitor to Pfizer's Vyndaqel. (reuters.com)
Analysts have raised price targets for Alnylam, with Stifel increasing its target to $345, indicating confidence in the company's growth prospects. (webull.com)
Alnylam's revenue growth of 28.35% as of June 30, 2024, demonstrates strong financial performance and potential for future profitability. (benzinga.com)
Goldman Sachs downgraded Alnylam to 'Neutral' and reduced the price target to $173 due to delays in the HELIOS-B study and competitive pressures. (investing.com)
Alnylam reported a net margin of -1115.71%, indicating significant challenges in achieving profitability. (benzinga.com)
Morgan Stanley reduced Alnylam's price target to $268, reflecting concerns over the company's financial outlook. (reporter.am)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
ALNY Financial Performance
Revenues and expenses
ALNY Earnings Performance
Company profitability
ALNY News
AllArticlesVideos
Alnylam Pharmaceuticals Names Garg R&D Chief
Market Watch·2 days ago
Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer
Business Wire·2 days ago
Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Alnylam Pharmaceuticals stock?
Alnylam Pharmaceuticals (ALNY) has a market cap of $41B as of June 20, 2025.
What is the P/E ratio for Alnylam Pharmaceuticals stock?
The price to earnings (P/E) ratio for Alnylam Pharmaceuticals (ALNY) stock is 0 as of June 20, 2025.
Does Alnylam Pharmaceuticals stock pay dividends?
No, Alnylam Pharmaceuticals (ALNY) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Alnylam Pharmaceuticals dividend payment date?
Alnylam Pharmaceuticals (ALNY) stock does not pay dividends to its shareholders.
What is the beta indicator for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals (ALNY) has a beta rating of 0.3. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.